Hot on the heels of a $150 million fundraise, Atsena Therapeutics is back with early-stage data for the company’s eye disease ...

Channel Therapeutics reports CT2000 reduced eye pain in preclinical trials, with plans to enter human testing for acute and ...

A Philadelphia entrepreneur developing eye repair tech stood out among international contenders as it gears up to raise a seed round.

Norwich Research Park biotech company, Ikarovec, has appointed ophthalmology drug development specialist Dr Thomas Ciulla as ...

Swiss pharma giant Roche is investing $280 million to build a new biopharma manufacturing facility in Shanghai, as it doubles ...

With growing uncertainty in the US, Chinese companies are swooping in to present themselves as stable, open partners to the ...

IN BRIEFUS Patent Office granted Active Biotech's patent application for laquinimod in eye disorders (January 28)Active Biotech announced that the first patient was enrolled in the European ...